Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥ 100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2024-09-02
DOI
https://doi.org/10.1093/eurheartj/ehae614
Citations
22
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
12.60

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

José Carlos Nicolau, A. Michael Lincoff, Philippe Gabríel Steg, Vijay Kunadian et al.
22 citations
European Heart Journal
Lipoproteins and Cardiovascular Health
12.60
article

Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

José Carlos Nicolau, A. Michael Lincoff, Philippe Gabríel Steg, Vijay Kunadian, Alan Yean Yip Fong, Basil S. Lewis, Manuel Horna, Thomas J. Povsic, Alexander Parkhomenko, Deepak L. Bhatt, Gemma Alexandra Figtree, Angel R. Cequier, Dragoş Vinereanu, Christoph Bode, Roxana Mehran, Kevin R. Bainey, Jack Tan, Frank M. Sacks, Nebojša Tasić, Stuart Pocock, Vibeke Juliebø, Pierluigi Tricoci, Andrejs Ērglis, Emil Hagström, Philip E. Aylward, João Morais, Lesley Burgess, Ümit Güray, Giuseppe Ambrosio, Kenneth W. Mahaffey, Sergey Zenin, Peter Libby, Bronwyn A. Kingwell, Stephan Windecker, Mika Laine, Stephen James Nicholls, Jarosław Trębacz, Pascal Vranckx, Robert A. Harrington, Miroslav Solař, Nina Gotcheva, Anthony Gershlick, Juan Carlos Prieto, Gerald Chi, Renato D. Lópes, John Hunter Alexander, Serge Korjian, Michał Tendera, Cecilia Bahit, John J.P. Kastelein, Kurt Huber, Piyamitr Sritara, Mark Heise, Daniel Duerschmied, Miguel Urina‐Triana, Béla Péter Merkely, Marc P. Bonaca, Michael Lee, Basil S. Lewis, Satoshi Yasuda, Danielle Duffy, Jose Luis Leiva Pons, Rimvydas Šlapikas, Shaun G Goodman, M. Cecilia Bahit, Christoph Bode, Gilles Montalescot, Jan Murin, Dimitris Tousoulis, Jiunn-Lee Lin, Tamaz Shaburishvili, Margus Viigimaa, Jan Murin, Amadeu Betriu, Ospedale S di Perugia
article en
22 citations

Abstract

In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥ 100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.

European Heart JournalVol. 45(47)
Brigham and Women's Hospital (US), St. Michael's Hospital (CA), Beth Israel Deaconess Medical Center (US), University Health Network (CA), Harvard University (US), Radboud University Nijmegen (NL), Inserm (FR), University of Freiburg (DE), Carol Davila University of Medicine and Pharmacy (RO), Université Paris Cité (FR), Cornell University (US), Alberta Hospital Edmonton (CA), University Medical Center Freiburg (DE), Auckland City Hospital (NZ), Health Sciences Centre (CA), University of Alberta Hospital (CA), Radboud University Medical Center (NL), Cleveland Clinic Lerner College of Medicine (US), Clinical Research Institute (US), St Michael’s Hospital (IE), London School of Hygiene & Tropical Medicine (GB), Noordwest Ziekenhuisgroep (NL), Assistance Publique – Hôpitaux de Paris (FR), Canadian VIGOUR Centre (CA), CSL (United States) (US), Carmel Medical Center (IL), Instituto de Neurología Cognitiva (AR), Duke Medical Center (US), Stanford Medicine (US), South Australian Health and Medical Research Institute (AU), Hôpital Bichat-Claude-Bernard (FR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Instituto do Coração (PT), Center for Clinical Research (United States) (US), CSL (Australia) (AU), Weill Cornell Medicine (US), Monash University (AU), Case Western Reserve University (US), Stanford University (US), Icahn School of Medicine at Mount Sinai (US)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, FibroGen, Cleveland Clinic, AtriCure, Bayer Corporation, CSL Behring, Boston Scientific Corporation, Regeneron Pharmaceuticals, Intarcia Therapeutics, Amarin Corporation, ReCor Medical, Kowa Company, Janssen Scientific Affairs, XBiotech, CryoLife, Moderna, York University, Daiichi-Sankyo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Novo Nordisk, Jewish General Hospital, Servier, Idorsia Pharmaceuticals, HLS Therapeutics, MicroPort, Akebia Therapeutics, Sanofi Australia, Esperion Therapeutics, National Institutes of Health, U.S. Food and Drug Administration, Genentech, American Regent, Duke Clinical Research Institute, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 1%
Lipoproteins and Cardiovascular Health
12.60
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.